Attention Deficit Hyperactivity Disorder — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for attention deficit hyperactivity disorder. 27 active patents protecting 3 drugs from 3+ originators. First major cliff: 2032. Daily refresh.

3
Approved drugs
27
Active US patents
53/100
Avg vulnerability
$172M
Annual revenue covered

Originators in Attention Deficit Hyperactivity Disorder

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Azurity 14 patents Novartis 9 patents Lavipharm 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating attention deficit hyperactivity disorder. Each bar = one year. Y-axis scaled to peak year (14 patents).

2
27
2
31
6
32
14
37
3
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Amphetamine Sulfate
AMPHETAMINE SULFATE
 Azurity 14 51 $172M 2037-03-10
Ritalin
methylphenidate
 Novartis 9 54 — 2032-06-28
Catapres-Tts-1
CLONIDINE
 Lavipharm 4 54 — 2027-04-17

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11896562 Amphetamine Sulfate method of use 75 2037-03-10
11896562 Amphetamine Sulfate method of use 75 2037-03-10
11896562 Amphetamine Sulfate method of use 75 2037-03-10
11896562 Amphetamine Sulfate method of use 75 2037-03-10
11166947 Ritalin method of use 70 2038-01-25
11166947 Ritalin method of use 70 2038-01-25
11166947 Ritalin method of use 70 2038-01-25
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8337890 Catapres-Tts-1 formulation 60 2027-04-17
8623409 Catapres-Tts-1 formulation 48 2031-09-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11160772 Amphetamine Sulfate formulation 42 2037-03-10
11160772 Amphetamine Sulfate formulation 42 2037-03-10
10441554 Amphetamine Sulfate formulation 42 2037-03-10
10441554 Amphetamine Sulfate formulation 42 2037-03-10
11160772 Amphetamine Sulfate formulation 42 2037-03-10
10441554 Amphetamine Sulfate formulation 42 2037-03-10
10441554 Amphetamine Sulfate formulation 42 2037-03-10
11160772 Amphetamine Sulfate formulation 42 2037-03-10
11160772 Amphetamine Sulfate formulation 42 2037-03-10
10441554 Amphetamine Sulfate formulation 42 2037-03-10

Related